arrow
D

Dirk Schadendorf

essen university hospital
H指数:182
被引数:22.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial

瑞利替尼单抗联合纳武利尤单抗对比纳武利尤单抗治疗晚期黑色素瘤:RELATIVITY-047 III期试验5年生存率及生物标志物分析

2026-10-240
OAAI
Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial

体外光opheresis治疗免疫检查点抑制剂疗法所致的类固醇难治性免疫相关不良反应:一项多中心Ib/II期临床试验

2026-10-230
OAAI
Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC-TRIM registry

免疫抑制状态对avelumab治疗晚期默克尔细胞癌真实世界结局的影响:前瞻性MCC-TRIM登记研究的结果

2026-10-100
PRE
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

原发性黑色素瘤假阴性诊断患者的生命损失年数。一项涉及9063例患者、为期28年的德国中央恶性黑色素瘤登记研究的回顾性研究

2026-07-020
OAAI
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients-a retrospective DeCOG study

PD-1抑制剂联合仑伐替尼作为经治晚期黑色素瘤患者治疗方案的现况数据——一项回顾性DeCOG研究

2026-03-260
PRE
Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment – Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg

接受靶向治疗和抗血栓治疗的晚期黑色素瘤患者的总体和无进展生存期得到提高-来自一项多中心研究的见解,涉及来自前瞻性皮肤癌登记处ADOReg的1296名患者

2025-12-190
OAAI
Messages for ultraviolet-radiation protection to fair-skinned populations

关于紫外线防护的信息,面向肤色较浅的人群

2025-11-060
OAAI
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

撤稿说明:sFRP2在衰老微环境中驱动黑色素瘤转移和疗法抵抗

Nature
IF48.5
2025-10-290
OAAI
Exceptional therapeutic benefit of imatinib in cKIT-mutated mucosal melanoma followed by a KIT mutation loss

cKIT突变黏膜黑色素瘤中伊马替尼的显著治疗获益及其随后发生的KIT突变丢失

2025-10-250
OAAI
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

辅助性尼沃鲁单抗和雷拉利单抗在III/IV期黑色素瘤中的应用:随机III期RELATIVITY-098试验

2025-10-180
OAAI
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification

利用自动CT体成分分析杠杆化肌肉减少症指数,用于泛癌种预后分层。

2025-10-140
OA
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study

妊娠期晚期黑色素瘤:一项回顾性、多中心、基于注册研究的建议

2025-10-070
OAAI
Outcome of systemic therapy in patients with advanced rare skin cancers: a retrospective multicenter DeCOG study of 209 patients

晚期罕见皮肤癌患者系统性治疗的结局:一项包含209名患者的回顾性多中心DeCOG研究

2025-08-300
PREAI
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG

晚期转移性黑色素瘤的性别特异性生存率——一项DeCOG研究,涉及ADOREG多中心前瞻性皮肤癌登记研究的2032例患者。

2025-07-290
OA